Characteristics of the study population: comparison of non-participants, participants and Swiss controls.

NOTE: Percentages are based upon available data for each variable.Abbreviations: GHD, growth hormone deficiency; IGHD, isolated growth hormone deficiency; ISS, idiopathic short stature; MPHD, multiple pituitary hormone deficiency; n, number; n.a., not applicable/ not available; rhGH, recombinant human growth hormone; SD, standard deviation; SDS, standard deviation score; SGA, small for gestational ageaNon-participants include 37 who were not included into mailing, 129 who did not respond and 85 who refused to participate.bAge and sex standardized numbers and percentages are given for Swiss controls.cColumn percentages are given.dp-value calculated from chi-square statistics comparing rhGH patients participants vs. non participants.ep-value calculated from chi-square statistics comparing rhGH patients participants vs. Swiss controls.fInformation not available for non-responders.gInformation on rhGH treatment is not applicable for Swiss controls.hOther indications include calciopenic rickets, osteogenesis imperfecta, central diabetes insipidus, clinically defined syndromes (except Turner syndrome), skeletal dysplasia, insufficient nutrient intake, disorders in organ systems, psychosocial growth failure, congenital adrenal hyperplasia.iGroup I includes healthy patients with IGHD or ISS; Group II patients with associated diseases or syndromes; Group III childhood cancer survivors with GHD.kp- value calculated on two-sample mean-comparison test (t-test).Characteristics of the study population: comparison of non-participants, participants and Swiss controls.